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Abstract
Background: The underlying nature of negative symptoms in psychosis is poorly understood.
Investigation of the relationship between the different negative subsymptoms and neurocognition
is one approach to understand more of the underlying nature. Apathy, one of the subsymptoms, is
also a common symptom in other brain disorders. Its association with neurocognition, in particular
executive functioning, is well documented in other brain disorders, but only studied in one former
study of chronic patients with schizophrenia. This study investigates the association between apathy
and neurocognitive functioning in patients with first episode psychosis (FEP), with the hypothesis
that apathy is more associated with tests representing executive function than tests representing
other neurocognitive domains.
Methods: Seventy-one FEP patients were assessed with an extensive neuropsychological test
battery. Level of apathy was assessed with the abridged Apathy Evaluation Scale (AES-C-Apathy).
Results: AES-C-Apathy was only significantly associated with tests from the executive domain
[Semantic fluency (r = .37, p < .01), Phonetic fluency (r = .25, p < .05)] and working memory [Letter
Number Span (r = .26; p =< .05)]; the first two representing the initiation part of executive
function. Confounding variables such as co-occuring depression, positive symptoms or use of
antipsychotic medication did not significantly influence the results.
Conclusion:  We replicated in FEP patients the relationship between apathy and executive
functioning reported in another study for chronic patients with schizophrenia. We also found
apathy in FEP to have the same relationship to executive functioning, as assessed with the Verbal
fluency tests, as that reported in patients with other brain disorders, pointing to a common
underlying nature of this symptom across disorders.
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Background
Negative symptoms are common in patients with psycho-
sis, but the underlying mechanisms are still poorly under-
stood [1]. Neurocognitive deficits are also common in
schizophrenia spectrum disorders, and are thought to be
more closely linked to the biological underpinnings of the
disorder than clinical symptoms [2]. As negative symp-
toms is repeatedly shown to have a consistent relationship
with neurocognitive deficits [3-6], a further exploration of
their relationship may aid the search for the mechanisms
behind negative symptoms. A recent review by Harvey et
al suggested four models as potential explanations for
their association [7]: 1) the two categories of symptoms
represent the same identical features or alternate manifes-
tations of the same basic underlying process, or 2) the two
features of the illness are separable but share similar
underlying etiological factors, or 3) the two are of sepa-
rate, but related etiologies, or 4) the two dimensions are
distinct from each other and with separate etiology. The
review concluded by inviting innovations in the assess-
ment of negative symptoms to come closer to an under-
standing of negative symptoms and other aspects of
psychosis [7].
One problem in studies of negative symptoms is the het-
erogeneity of patient samples examined, with an admix-
ture of chronic samples marked by treatment failures,
institutionalization, hopelessness and subsequent social
consequences that are difficult to distinguish from pri-
mary negative symptoms based solely on behavioral
observations. Another problem is the diverse nature of the
negative symptoms per se, as it includes several subsymp-
toms (apathy or avolition, anhedonia, alogia, asociality,
flat affect and inattention) that might have different etiol-
ogies. Based on the recognition of this diversity, the
"NIMH-MATRICS consensus statement on negative symp-
toms" has suggested that studies specific to the nature of
these negative subsymptoms is one way to move forward
[1]. So far, very few studies on the association between
negative symptoms and neurocognitive function have
included analysis on the subsymptom level. We have thus
found only four studies addressing the specific relation-
ship between any of the negative subsymptoms and neu-
rocognitive function [8-11]; the subsymptoms studied
being alogia [8,10] flat affect [8,11] and apathy [9].
Apathy, defined as lack of motivation or goal directed
behavior [12], has lately been targeted as an important
negative subsymptom that need further study [13-15].
However, the only study concerned with the association
between apathy and neurocognition in psychosis is based
on a small sample of chronic patients with schizophrenia
and a narrow test battery [9]. Here, a high level of apathy
was associated with lower performance IQ scores and
poor performance on tests assessing executive function
and visual- and verbal memory. The authors called for
new studies in order to generalize their findings, due to
the small sample size and lack of a comprehensive neu-
ropsychological test battery. Studying patients with their
first episode of psychosis (FEP) is of particular interest,
since the negative symptoms in such a sample cannot be
secondary to chronic effects, treatment failures or social
deprivation.
Apathy is considered a symptom arising from the prefron-
tal cortex [16] or from dysfunction in the frontal-subcor-
tical circuits [17]. It's relationship to neurocognitive
function has been extensively studied in other brain disor-
ders, such as Alzheimer – (AD) [18], Parkinson – (PD)
[19] and Huntington disease (HD) [20] in addition to
traumatic brain injury (TBI) [21]. Common to studies of
all the above disorders is the finding of a consistent rela-
tionship between high levels of apathy and poorer per-
formance on tests representing executive function [19-
24]. In addition, significant associations are found to
other neurocognitive domains, especially working mem-
ory [19,24], psychomotor speed [21], attention [20] and
episodic memory [20,21], but for these domains the pat-
tern of association is less systematic.
The aim of the present study is to improve our under-
standing of apathy in FEP patients. Consequently, we
wish to investigate the association between apathy and
neurocognitive function. First, we hypothesize that also in
FEP patients the degree of apathy will be significantly
related to tests representing executive function, and less
with tests representing other neurocognitive domains.
Secondly, we hypothesize that this relationship is not
influenced by confounding variables, such as depression,
use of antipsychotic medication or positive symptoms,




The present study includes 71 FEP patients with a fluent
understanding of Norwegian, recruited between July 2004
and end of June 2006. They all took part in both the clin-
ical and the neuropsychological assessment in the ongo-
ing Thematically Organized Psychosis (TOP) research
study in Oslo, Norway. All patients were assessed in a sta-
ble phase. The neurocognitive testing was done in as close
connection to the clinical assessment as possible, within
one to eight weeks. Inclusion criteria were: Age between
18 and 65 years, with a first episode of psychosis and a
DSM-IV diagnosis of either schizophrenia, schizophreni-
form disorder, schizoaffective disorder (constituting
schizophrenia spectrum disorders); psychosis NOS, delu-
sional disorder, brief psychosis (constituting other psy-
chotic disorders), or affective disorder with moodBMC Psychiatry 2009, 9:1 http://www.biomedcentral.com/1471-244X/9/1
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incongruent psychotic symptoms and bipolar disorder
(constituting affective psychotic disorders). Patients were
eligible for inclusion up to 52 weeks following the start of
the first adequate treatment. Being psychotic was defined
as having a rating of 4 or more on anyone of the PANSS
items P1, P3, P5, P6 or G9. Fifty seven (80.3%) of all used
antipsychotic medication (AP); 51 on monotheraphy and
six on two AP's. Of these 57, three were using first genera-
tion AP [Zuclopentixol (N = 2); Perphenazine (N = 1)]
and the rest second generation AP [Olanzapine (N = 28);
Risperidone (N = 9); Ziprazidone (N = 9); Quetiapine (N
= 7), Aripriprazole (N = 5) and Amisulpride (N 01)]. The
average Defined Daily Dosage of Antipsychotics (DDD-
AP) assignment according to the World Health Organiza-
tion was 1.08 (SD .61) [25]. Table 1 shows the demo-





Apathy was assessed by the clinical version of the Apathy
Evaluation scale (AES-C), an 18-item Likert scale ranging
from 0–4 (0 = not at all and 4 = very much) [26]. The scale
is based on Marin's definition of apathy as " diminished
motivation and goal directed behavior, not attributed to
diminished level of consciousness, general cognitive
impairment or emotional distress" [26]. Examples of the
questions are: "Are you interested in things?", "Is it impor-
tant for you to get things done during the day?" and "Do
you feel motivated?" The scale has been used across differ-
ent medical disciplines. We have previously shown that a
shortened 12-item AES-C scale (AES-C-Apathy) was a bet-
ter assessor of apathy than the full version in a population
with a FEP [27]. This abridged version was used in all the
analyses in the present study.
Assessment of other symptoms and diagnosis
Symptoms were assessed by the Structural Clinical Inter-
view of the PANSS (SCI-PANSS) [28]. Depression was
assessed with the Calgary Depression Scale for schizo-
phrenia (CDSS) [29]. Diagnostic assessment was carried
out with the Structural Clinical Interview for DSM-IV
(SCID-I interview) [30].
2.3 Neuropsychological assessments
A comprehensive neuropsychological test battery was
administrated to all participants by psychologists or psy-
chology students trained in clinical neuropsychology. The
tests cover domains shown to be sensitive to the neuro-
cognitive dysfunction of psychosis [31,32]: motor func-
tion (Grooved Pegboard) [33], psychomotor speed (Digit
Symbol from WAIS-III) [34], attention (Digit Span for-
wards from WAIS-III) [34], working memory (Letter
Number Span from WAIS-III) [34], verbal learning (Cali-
fornia Verbal Learning Test; CVLT-II) [35], visual learning
(Rey-Oesterrieth Complex Figure Test) [36] and executive
function. For the executive function domain several tests
from the Delis-Kaplan Executive Function System (D-
KEFS) [37] were included in order to enable the investiga-
tion of the association of apathy with three different
aspects of executive function; initiation, set shifting and
inhibition. Initiation was assessed with Semantic fluency
and Phonetic fluency (from the Verbal Fluency test) [37].
Table 1: Sociodemographic and clinical variables for 71 FEP 
patients
Mean SD
Age (years) 27.4 8.1
Education (years) 12.5 2.7
DUP (weeks) median/range 30 1–1040
GAF symptoms 42.8 14.0
GAF function 46.1 14.4
AES-C-Apathy 27.2 7.1
PANSS total score 60.5 15.1
PANSS positive 14.4 5.1
PANSS negative 14.7 5.8
PANSS general 31.3 7.4
CDSS 6.4 4.5
N%
Male gender 37 52%
Living alone 63 89%
Diagnosis
Schizophrenia spectrum group 36 51%
Affective psychosis gorup 15 21%
Other psychosis group 20 28%
Abbreviations: DUP, duration of untreated psychosis; GAF, Global 
Assessment of Functioning Scale; PANSS, Positive and Negative 
Syndrome Scale; CDSS, Calgary Depression Scale for Schizophrenia; 
Schizophrenia spectrum group [schizophrenia (N = 30), 
schizophreniform (N = 6)]; Affective psychosis group [major 
depressive psychosis with mood incongruent psychosis (N = 12), 
Bipolar (N = 3)]; Other psychosis group [psychosis NOS (N = 13, 
brief psychosis (N = 6), delusional disorder (N = 1)]BMC Psychiatry 2009, 9:1 http://www.biomedcentral.com/1471-244X/9/1
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Set shifting was assessed with Category Switching (also
from the Verbal Fluency test) [37], whereas inhibition was
measured with the third trial on the Color-Word Interfer-
ence test (the "Stroop" condition) [37]. Premorbid IQ was
assessed with a Norwegian Research version of the
National Adult Reading Test (NART) [38]; and current IQ
with Wechsler Abbreviated Scale of Intelligence (WASI;)
[39]. All participants showed adequate neuropsychologi-
cal test effort indicated by two errors or less on the forced
recognition trial of the CVLT-II. Table 2 gives the test
results of the 71 patients.
2.4 Procedures
All participants gave written informed consent to partici-
pate, and the study was approved by the Regional Com-
mittee for Medical Research Ethics and the Norwegian
Data Inspectorate. The data file has received an Audit Cer-
tificate from the Center for Clinical research at Ullevål
University Hospital.
The three investigators who did all the clinical assess-
ments in the current study completed the common train-
ing and reliability program of the TOP study. Training in
the AES-C was done by scoring videos, supervised by two
experienced clinicians who had previously used the scale
with other patient groups [40], and reliability testing of
the AES-C was completed by seven live interviews with
random study patients. The SCID training was based on
the UCLA training program [41], and supervised by
UCLA. For DSM-IV diagnostics, mean overall kappa for
the standard diagnosis of training videos was 0.77, and
mean overall kappa for a randomly drawn subset of actual
study patients was also 0.77 (95% CI 0.60–0.94). Inter-
rater reliability (Intra Class Coefficient (ICC) 1.1) for the
different psychometric scales were: PANSS positive sub-
scale 0.82 (95% CI 0.66–0.94) PANSS negative subscale
0.76 (95% CI 0.58–0.93), PANSS general subscale 0.73
(95% CI 0.54–0.90), GAF-S 0.86 (95% CI 0.77–0.92),
GAF-F 0.85 (95% CI 0.76–0.92) and AES-C 0.98 (95% CI
0.92–0.99).
2.5 Analyses
2.5.1 Data and statistical analyses
Analyses were performed with the statistical package SPSS,
version 15.0 for Windows. A preliminary analysis was per-
formed to examine the distribution of each variable. One
patient was excluded because of being an extreme outlier
on the Semantic fluency tests with 4 SD above the group
mean (outlier score = 75; group mean = 40.1, SD = 8.6)
influencing the results to such a degree that assumptions
of homogeneity were violated. All tests were two-tailed,
with a preset significance level of 0.05. Bonferroni correc-
tions were applied in analyses where more than one test
represented a neurocognitive domain, as noted in Table 3.
Descriptive data are presented by either means or stand-
ard deviation (SD), or by median and range. Independent
Student t-tests were used to analyze differences between
groups. Associations between AES-C-Apathy and neu-
ropsychological tests were investigated with Pearson
Table 2: Neuropsychological test results for 71 FEP patients
Test Mean SD
IQ
NART (N = 66) 14.4 7.3
WASI (N = 71) 105.2 13.7
Motor function
Grooved Pegboard (N = 70) 110.2 26.5
Psychomotor speed
Digit Symbol (N = 71) 63.5 14.4
Attention
Digit Span forward (N = 71) 5.8 1.1
Verbal memory
CVLT-II (N = 71) 53.0 10.5
Visual memory
ROCF long term memory (N = 65) 19.5 6.7
Working memory
Letter Number Span (N = 65) 9.7 2.5
Executive function
Initiation
Phonetic fluency (N = 71) 38.4 11.9
Semantic fluency (N = 71) 39.6 7.6
Set shifting
Category switching (N = 71) 12.4 2.7
Inhibition
Color-Word Interference (N = 71) 60.0 21.0
Abbreviations: NART, National Adult Reading test; WASI, Wechsler 
Abbreviated Scale of Intelligence; CVLT-II, California Verbal Learning 
Test II; ROCF, Rey-Osterrieth Complex Figure Test.BMC Psychiatry 2009, 9:1 http://www.biomedcentral.com/1471-244X/9/1
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Table 3: Correlation between neuropsychological tests, AES-C-Apathy and possible confounding variables
Test (N) AES-C-Apathy CDSS PANSS Positive DDD-AP
rr r r
IQ
Premorbid: NART .11 <.01 .25* .11
Current: WASI -.15 -.02 -.11 -.23
Motor function
Grooved Pegboard .09 -.02 .14 .18
Psychomotor speed
Digit symbol -.17 -.04 -.11 -.15
Attention
Digit span forwards -.13 .02 .04 -.14
Verbal memory
CVLT-II -.15 .05 -.15 -.13
Visual memory
ROCF long term memory -.16 -.05 -.10 -.21
Working memory
Letter Number Span -.26* -.07 -.13 -.13
Executive function
Initiation
Phonetic fluencya -.25* -.08 < -.01 -.17
Semantic fluencya -.37** -.05 -.04 -.11
Set shifting
Category switching -.18 .06 .02 -.24*
Inhibition
Color-Word Interference .23 .10 .25* .10
r = Pearson product moment correlation; *p <.05; a Bonferroni corrected (0.05/2 = .03) * = p ≤ .03; ** = p ≤ .01
Abbreviations: NART, National Adult Reading Test; WASI, Wechsler Abbreviated Scale of Intelligence; CVLT-II, California Verbal Learning Test II; 
ROCF, Rey-Osterrieth Complex Figure Test; AES-C-Apathy, abridged Apathy Evaluation Scale; CDSS, Calgary Depression Scale for Schizophrenia; 
PANSS, Positive and Negative Syndrome Scale; DDD-AP, indicates defined daily dose according to the World Health Organization of Antipsychotic 
medicationBMC Psychiatry 2009, 9:1 http://www.biomedcentral.com/1471-244X/9/1
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product moment correlation analysis (r) and degree of
influence by univariate regression analysis.
Since apathy, negative symptoms and neurocognitive
function have been found to be under influence from sec-
ondary sources, we took steps to control for this. Depres-
sion has been tested as a possible confounding variable
for apathy in different studies in other medical disciplines
[18,21], in addition positive symptoms and current use of
antipsychotic medication has in some studies been found
to influence either negative symptoms or neurocognitive
function [42]. The association between these three varia-
bles and neurocognition were firstly examined in a corre-
lation analysis followed by a hierarchical multiple
regression analysis with the neurocognitive test results as
the dependent. The possible confounders and AES-C-Apa-
thy were the independent variables, with AES-C-Apathy
entered in the last step.
Results
3.1 The relationship between apathy, neuropsychological 
test performance and confounding variables
Three of the neuropsychological tests in the comprehen-
sive TOP battery showed a statistically significant inverse
association to AES-C-Apathy (Table 3). Out of these two
(Semantic- and Phonetic fluency part of the Verbal Flu-
ency tests) represented the initiation part of executive
function, and the third (Letter Number Span) represented
working memory. AES-C-Apathy was most strongly corre-
lated with the Semantic fluency test (r = .37, p = .002),
explaining 12% of its variance. For the two other tests
(Phonetic fluency and Letter Number Span) the relation-
ship to AES-C-Apathy was statistically significant, but of a
smaller magnitude (r = .25, r = .26). AES-C-Apathy was
neither significantly associated with any other tests, nor
premorbid or current IQ.
There were no statistically significant differences in test
performance for any neuropsychological tests (p value
between .18 – .99) or in level of apathy (F = .16; p = .69)
between the unmedicated patients (N = 14) and patients
using antipsychotic medication (N = 57). None of the
possible confounding variables (DDD-AP, PANSS posi-
tive symptoms or CDSS) had any significant correlations
with the three neuropsychological tests that were statisti-
cally significantly associated with AES-C-Apathy (Table
3). This lack of influence was confirmed in a hierarchical
regression analysis with Semantic-, Phonetic fluency and
Letter Number Span as dependent variables. Here only
AES-C-Apathy had a statistically significant contribution,
even when entered in the last step (Table 4). The entry of
the possible confounding variables did not change the
influence AES-C-Apathy had on the neuropsychological
tests in the univariate regression analysis (Table 4).
Discussion
The main result of the present study is the replicated find-
ing of a significant relationship between apathy and exec-
utive function in psychotic disorders, as found previously
in one study of patients with chronic schizophrenia [9].
The two findings are corresponding even if the two studies
applied different measures both for apathy and executive
Table 4: Univariate and hierarchial multivariate regression analysis with neuropsychological tests as dependent and AES-C-Apathy and 
possible counfounders as independent variables
Dependent Dependent Dependent
Letter Number Span Phonetic fluency Semantic fluency
Independent variables R2adj β tp R 2 adj β tp R 2 adj β tp
Univariate
AES-C-Apathy .05 -.26 -2.2 .04 .05 -.25 -2.2 .03 .12 -.37 -3.3 <.01
Hierarchial
DDD-AP .01 -.13 -1.1 .30 .02 -.19 -1.6 .12 .00 -.12 -1.0 .31
PANSS positive .01 -.06 -.5 .62 .01 .07 .6 .56 -.01 .04 .3 .75
CDSS -.09 .05 .3 .72 -.02 .05 .4 .72 -.03 .15 1.2 .25
AES-C-Apathy .04 -.27 -2.0 .05 .05 -.29 -2.2 .03 .12 -.44 -3.5 <.01
adj = adjusted; DDD-AP, indicates defined daily dose according to the World Health Organization of antipsychotic medication PANSS, Positive and 
Negative syndrome Scale; CDSS, Calcary Depression Scale for Schizophrenia; AES-C-Apathy, abridged Apathy Evaluation ScaleBMC Psychiatry 2009, 9:1 http://www.biomedcentral.com/1471-244X/9/1
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function, indicating a robust relationship. In addition, in
both studies the relationship was not influenced by cur-
rent level of depression. This supports the view that the
presence of apathy and deficits in executive functioning
are related in psychotic disorders, and that the relation-
ship is not due to definitional issues since different scales
and tests were used.
Additionally, this finding is in line with findings of an
association between apathy and the specific executive
functioning test of verbal fluency in several other brain
disorders [18-20,22]. Two of these studies used the AES in
assessing apathy [19,22], eliminating the challenge of
comparing results between different scales.
This finding of a consistent relationship between apathy
and tests of executive function across different brain disor-
ders and across different levels of chronicity is supported
by several studies that implicate prefrontal areas and fron-
tal-subcortical circuitry involving the anterior cingular
gyrus in both apathy and executive function [43-47].
In our opinion, our findings thus support the idea of a
common or linked etiology between these negative symp-
toms and neurocognitive deficits as put forward in Harvey
et al's model 2 and 3 [7]. This is in opposition to Harvey's
own conclusions, that suggests that the two have different
etiologies based on a lack of published studies showing
significant relationships. In addition, our findings might
imply that there are specific mechanisms behind the dif-
ferent negative subsymptoms. This is supported by a
recent study finding that verbal memory was the only neu-
ropsychological test to differentiate between those with
and without flat affect, making the authors' suggest that
this could reflect a unique neural substrate for this nega-
tive subsymptom [11].
We did not, as Roth et al, find associations between high
levels of apathy and reduced IQ and memory, associations
with apathy that are also found in other disorders. This
could be due to the differences between the studies such
as assessment of apathy, FEP patients being less chroni-
cally ill and diagnostically more diverse. But in order to
understand more of the different negative subsymptoms,
these associations should also be further studied.
The strength of our study is the use of a specific and vali-
dated assessment for the negative subsymptom of apathy
together with a comprehensive neuropsychological test
battery with tests for several different aspects of executive
function. The main limitations to our study are: 1) that we
only had access to instruments measuring one of the spe-
cific negative subsymptoms and thus cannot conclude
anything about the specificity of our finding in regard to
the other subsymptoms. 2) that for some patients the clin-
ical assessment of apathy and the neuropsychological test-
ing took place with a time difference and this could
weaken our chances to detect weaker associations.
Conclusion
First we replicated the finding in FEP patients, as was
found in chronic patients, of a significant relationship
between apathy and executive functioning. Second, we
found that apathy in FEP have the same relationship to
the Verbal Fluency test, as reported in other brain disor-
ders, pointing to a common underlying nature of this
symptom across disorders.
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